Unia Europejska -
słowacki -
EMA (European Medicines Agency)
ronapreve
roche registration gmbh - casirivimab, imdevimab - covid-19 virus infection - imunitný séra a imunoglobulíny, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. pozri časti 4. 4 a 5.
Unia Europejska -
słowacki -
EMA (European Medicines Agency)
gavreto
roche registration gmbh - pralsetinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.
Unia Europejska -
słowacki -
EMA (European Medicines Agency)
lunsumio
roche registration gmbh - mosunetuzumab - lymfóm, folikulárny - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
Unia Europejska -
słowacki -
EMA (European Medicines Agency)
vabysmo
roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologiká - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).
Unia Europejska -
słowacki -
EMA (European Medicines Agency)
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - antineoplastické činidlá - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
